AzTrials
AzTrials

AdhdNCT02318017

Psychostimulants Effects on Brain Functional Connectivity in Youth With Attention Deficit Hyperactivity Disorder

A study testing Methylphenidate in people with Adhd, run by Sheba Medical Center at 1 site in Israel.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

In the current study, we will administer three widely administered cognitive tasks while simultaneously measuring electroencephalography (EEG) in ADHD patients before and after methylphenidate immediate release (IR) treatment compared to placebo. Read more about this study

Who is it for?
Ages 6 to 18 yearsHealthy volunteers can take part
Conditions the study is for
Adhd
What is being tested?
Methylphenidate
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
75 participants
Where
1 siteIsrael
Study dates
Dec 2014to Dec 2017
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 to 18 years
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult

Who may be able to join

  • Children and adolescents which are being considered for methylphenidate treatment and therefore referred to computerized cognitive tasks with and without methylphenidate IR use as part of their management

Who cannot join

  • study group: Age fewer than 6 and above 18, history of seizure, head trauma, substance abuse or medication other than stimulants, inability to swallow pills.
  • control group: Age fewer than 6 and above 18, history of seizure, head trauma, substance abuse, current medication use. Current or lifetime psychiatric disorders.

Trial locations and contacts

1 site in 1 country.

Itai Horowitz, MD contact

972503370579

itaizen@gmail.com

Israel1 site
  • Sheba medical center

    Tel HaShomer

Other trials in Israel

About this study

Official title: An Electroencephalography Study of the Effects of Psychostimulants on Dynamic Patterns of Cognitive Task-based Functional Connectivity in Youths With Attention Deficit Hyperactivity Disorder

In the current study, we will administer three widely administered cognitive tasks while simultaneously measuring electroencephalography (EEG) in ADHD patients before and after methylphenidate immediate release (IR) treatment compared to placebo. In addition we will compare the effective connectivity dynamics to normal subjects. Using this novel network analysis approach, we will attempt to address the currently limited cognitive network literature. We will attempt to map the connectivity between the discrete brain regions during the execution of the tasks before and after treatment with methylphenidate IR. Comparison with healthy control subjects will enable us to determine whether the direction of methylphenidate induced changes in brain functioning (in youths with ADHD) will be toward or away from normal connectivity patterns. We will also examine whether network patterns differ between the healthy controls and the ADHD patients.

Read the detailed description

Research objective:

To examine dynamic patterns of task-evoked network connectivity in ADHD patients before and after methylphenidate IR treatment compared with healthy controls.

Aims:

  1. To explore whether patterns of network connectivity differs before and after methylphenidate treatment.
  2. To explore whether patterns of network connectivity differs between ADHD patients and healthy subjects.

Methods

Subjects Total number of subjects: 55 age 6-18, the widest age range for representation of pediatric population not including preschoolers. The cross-over study design of this study is best suited for a wide study population age range. Preschoolers will not be included because of incompatibility of the computerized neurocognitive tasks.

35 children and adolescent patients undergoing diagnosis and treatment management for ADHD using computerized cognitive tasks (e.g. CPT) with and without methylphenidate treatment.

20 healthy children and adolescents will be recruited.

Recruitment procedure in the study will be as follows:

  1. Parents of patients diagnosed with ADHD will be approached at the attention clinic of the Sheba Medical Center to check whether they wish to participate in the study. It should be emphasized that treatment and follow-up at the clinic will not be affected by the participation or non-participation in the study.
  2. E-mail and/or phone contact will be made to parents of patients diagnosed with ADHD from the attention clinic of the Sheba Medical Center. Only parents who confirmed in advance (and regardless of the current study) to contact them by e-mail and / or phone will be contacted.
  3. During lectures to the general public, performed by the researchers on the subject of ADHD, the research will be presented and offered for parents of ADHD diagnosed child to participate in the study. Information letter will be sent (study group recruitment add attached) to all who express interest of his son / daughter participation in the study.
  4. Recruitment of participants in the control group - recruitment announcement of healthy volunteers will be sent using electronic media and shall be accompanied by an information letter (control group recruitment add- attached).

Study group

Children and adolescents which are being considered for methylphenidate treatment and therefore referred to computerized cognitive tasks with and without methylphenidate IR use as part of their management. The recruitment will be from patients referred to the attention clinic at Edmond and Lilly Safra children's Hospital and diagnosed with ADHD. Patients treated with methylphenidate or under consideration for treatment with methylphenidate will be offered to join the study and will be included in the study after the proper consent forms will be signed by them and their parents. Clinical assessment including semi constructed interview by a psychiatrist as part of the regular management will be made.

Control group Healthy children and adolescents will be recruited after signing the proper consent forms by them and their parents. Public publication of the study will take place for the recruitment of the control group. (e.g posters stating the main study objectives, procedures and the subjects needed characteristics)

Recruitment and payment Subjects' parents will be paid only for carfare and loss of time.

Medication: Subjects from the control group already using methylphenidate will have at least 2 days medication wash out prior to the evaluation day.

Methylphenidate IR will be given as a single dose of 0.5 mg/kg.

Experimental design 1. Demographic measures: General demographics questionnaire - i.e. name, gender, age, country of origin, level of education.

  1. Neuropsychiatric and side effects assessment:
  2. The DuPaul-Berkley ADHD Rating scale - Hebrew version, will be used at baseline session. (Dupaul GJ 1991)
  3. Hebrew version of the schedule for Affective disorders and Schizophrenia for school-aged Children, present and lifetime (K-SADS-PL) (Kaufman et al. 1997).
  4. Berkley side effects rating scale (modified Hebrew version) will be administered to parents after methylphenidate-IR/placebo. (Berkley RA 1988)
  5. The Strengths and Difficulties Questionnaires (SDQ) - Hebrew version, will be used at baseline session for the control group. (Goodman R 1997)
  6. Clinical Global Impression - Severity scale (CGI-S) (Guy W, 1976)
  7. Clinical examination including psychiatric interview and assessment for soft neurological signs.
  8. EEG testing procedure: A 64 channel ActiveTwo Biosemi EEG system (Biosemi Instrumentations, Amsterdam, Netherlands) will be used to record task-related evoked potentials over the entire scalp. Sampling rate at 1024 Hz. ActiveTwo Biosemi EEG system allows calibration changes which are not required for clinical treatment and is used for research purposes only. The ActiveTwo Biosemi EEG system is not used for outpatient or inpatient clinical use in Israel. In this study we will use the ActiveTwo Biosemi EEG system from the Weizmann institute at Sheba medical center. Subjects will be seated comfortably in a chair and the Biosemi cap put on their head. The 64-scalp electrodes are positioned according to the international 10-20 system. To place the cap, we will measure the distance between the nasion and inion and the distance between the two ears and situated the cap so that electrode Cz was exactly half way between the two ears and between nasion (intersection of the frontal bone and two nasal bones) and inion (external occipital protuberance).

Baseline EEG measure: Prior to the cognitive testing, a baseline EEG recording of 5 minutes will be required to generate a baseline network map of brain connectivity.

Cognitive EEG measure: Throughout the cognitive testing (detailed below), EEG will be recording the neural response and the data will be processed offline.

  1. Cognitive tasks:
  2. Sustained attention and cognitive inhibition The Sustained Attention to Response Task (SART): The SART requires participants to make frequent responses to non-targets and to withhold a response to rarely presented targets. The task simply involves the sequential presentation of 297 single pictures (33 of each kind) presented over 6min. Subjects responded with a key press to each picture, except the 33 occasions when the designated picture appeared (refer to Figure 1). The response required to a non-target stimulus is simply the pressing of a mouse/keyboard, and targets are dispersed randomly in the sequence and occur no more often than 1 in 9 trials on average. In the SART, therefore, commission errors (failure to inhibit responding to a target) or "slips of action" are the result of brief lapses of sustained attention. In the Random SART, the target appears randomly therefore inhibition of a prepotent is essential as the requirement to inhibit a response is unpredictable. Therefore, this task looks at the ability to produce 'correct' inhibitions on inappropriate responses (Robertson et al., 1997). The SART has 4 measurable conditions:
  3. Go condition (pressing when required to press)
  4. Omission error (not pressing when required to press)
  5. No-Go condition (not pressing when required to refrain from pressing)
  6. Commission error (pressing when required to refrain from pressing)
  7. Working memory The n-back task: The n-back task examines a number of key processes required for working memory. These processes include on-line monitoring, updating information and the manipulation and retention of remembered information. In the task, participants are required to monitor a series of visual stimuli and to indicate when the currently presented stimulus is the same as the one presented n trials (n can be 0, 1, or 2) previously. To begin, in the 0-back condition, participants are required to response to a single pre-determined target picture. In the 1-back condition, the target picture is represented by any picture identical to the immediately preceding one (i.e., one trial back). In the 2-back condition, the target picture is represented by any picture identical to any picture that was presented two trials back. Therefore, the working memory load varies from 0 to 2 items.
  8. selective attention and cognitive inhibition The Stroop color and word Task: (Stroop, 1935) The requirements of the Stroop task is to inhibit the more automatic tendency to read a written word while performing the less automatic task of choosing the color of ink in which the word is written, as fast as possible. The participants are required to identify, as quickly as possible, the ink color of the Hebrew words: red, blue, green and yellow, presented in varying colors (red, blue, green and yellow) and press the correct key. The names of the colors will be printed onto keys on the keyboard (i for red, j for yellow, l for blue and m for green). When the participant presses the correct key, reaction time will be recorded, and the next stimulus appeared. Presentation of word stimuli will be divided into blocks, consisting of four blocks of 16 congruent or incongruent (50% each randomly) colored word stimuli. Maximum stimulus duration and interstimulus durations will be 1,300 and 350 msec, respectively. The task procedure is based on previous studies (Peterson et al. 2009). Procedural design Parents of children referred to the clinic for ADHD diagnosis and management will be offered to participate in the study. After the parents and participant signed the proper consent form a meeting for evaluation by a psychiatrist will be scheduled. If indeed an ADHD diagnosis is made and methylphenidate treatment is recommended the children will be recruited for the study. The treatment design will be double-blind placebo controlled cross-over. Half of the patients will receive methylphenidate immediate release (IR) first and then placebo and half will receive placebo first and then methylphenidate-IR in a randomized manner. The placebo and methylphenidate-IR pills (identical in appearance) will be placed for each subject in the study group in two cases marked "A" an "B", the content will be written by an RA separately which will decide the order (first placebo or first methylphenidate-IR) using a coin flip, and will be revealed only after the final session and after all questioners will be filled. Data analysis Data analysis will be made offline:
  • Data preprocessing and artifact correction (using EEGLAB): Eye-blink correction Cleaning for movement Filter data • Discrete Regions Analysis (using EEGLAB): Examine the averaged ERP Use t-tests to assess whether the ERP differs across conditions Provide a map of neural response to cognitive tasks • Network analysis (using matlab): Network construction (i.e. nodes, coefficient of cluster, small worldness) Examine network robustness
Conditions
Adhd
Being tested
Methylphenidate, Placebo
Keywords
adhd, global network, eeg
Medical subject headings
Attention Deficit Disorder with Hyperactivity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MethylphenidateDrug

    Also called MPH

    Before neurocognitive testing, Methylphenidate/Placebo will be given

  • PlaceboDrug

Study groups in NCT02318017
Study groupRoleWhat they receive
MethylphenidateActive comparatorMethylphenidate 0.5mg/kg - once
Receives: Drug: Methylphenidate
PlaceboPlacebo comparatorPlacebo - once
Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Baseline Complex Network connectivity before treatment - using electrodes signal correlation (P-value)

    Complex network is measured by metrics that are calculated using graph-theory analysis methods that enable the characterization of the architecture of complex networks. The network is constructed from the EEG signals by correlating the signals between all pairs of electrodes, assuming that each two electrodes that are correlated above a pre-determined threshold are functionally connected and with higher correlation the higher network connectivity. Assessed at baseline before MPH\Placebo according to the above time frames.

    Measured: 0 minutes

  2. Baseline Complex Network connectivity after treatment - using electrodes signal correlation (P-value)

    Complex network is measured by metrics that are calculated using graph-theory analysis methods that enable the characterization of the architecture of complex networks. The network is constructed from the EEG signals by correlating the signals between all pairs of electrodes, assuming that each two electrodes that are correlated above a pre-determined threshold are functionally connected and with higher correlation the higher network connectivity. Assessed at baseline after MPH\Placebo according to the above time frames.

    Measured: 90 minutes

Secondary outcomes (6)
  1. Complex Network connectivity at Sustained Attention task before treatment - using electrodes signal correlation (P-value)

    Complex network is measured by metrics that are calculated using graph-theory analysis methods that enable the characterization of the architecture of complex networks. The network is constructed from the EEG signals by correlating the signals between all pairs of electrodes, assuming that each two electrodes that are correlated above a pre-determined threshold are functionally connected and with higher correlation the higher network connectivity. Assessed at Sustained attention task before MPH\Placebo according to the above time frames.

    Measured: 11 minutes

  2. Complex Network connectivity at N-Back task before treatment - using electrodes signal correlation (P-value)

    Complex network is measured by metrics that are calculated using graph-theory analysis methods that enable the characterization of the architecture of complex networks. The network is constructed from the EEG signals by correlating the signals between all pairs of electrodes, assuming that each two electrodes that are correlated above a pre-determined threshold are functionally connected and with higher correlation the higher network connectivity. Assessed at N-Back task before MPH\Placebo according to the above time frames.

    Measured: 24 minutes

  3. Complex Network connectivity at the Stroop task before treatment - using electrodes signal correlation (P-value)

    Complex network is measured by metrics that are calculated using graph-theory analysis methods that enable the characterization of the architecture of complex networks. The network is constructed from the EEG signals by correlating the signals between all pairs of electrodes, assuming that each two electrodes that are correlated above a pre-determined threshold are functionally connected and with higher correlation the higher network connectivity. Assessed at the Stroop task before MPH\Placebo according to the above time frames.

    Measured: 30 minutes

  4. Complex Network connectivity at Sustained Attention task after treatment - using electrodes signal correlation (P-value)

    Complex network is measured by metrics that are calculated using graph-theory analysis methods that enable the characterization of the architecture of complex networks. The network is constructed from the EEG signals by correlating the signals between all pairs of electrodes, assuming that each two electrodes that are correlated above a pre-determined threshold are functionally connected and with higher correlation the higher network connectivity. Assessed at Sustained Attention task after MPH\Placebo according to the above time frames.

    Measured: 101 minutes

  5. Complex Network connectivity at N-Back task after treatment - using electrodes signal correlation (P-value)

    Complex network is measured by metrics that are calculated using graph-theory analysis methods that enable the characterization of the architecture of complex networks. The network is constructed from the EEG signals by correlating the signals between all pairs of electrodes, assuming that each two electrodes that are correlated above a pre-determined threshold are functionally connected and with higher correlation the higher network connectivity. Assessed at N-Back task after MPH\Placebo according to the above time frames.

    Measured: 114 minutes

  6. Complex Network connectivity at the Stroop task after treatment - using electrodes signal correlation (P-value)

    Complex network is measured by metrics that are calculated using graph-theory analysis methods that enable the characterization of the architecture of complex networks. The network is constructed from the EEG signals by correlating the signals between all pairs of electrodes, assuming that each two electrodes that are correlated above a pre-determined threshold are functionally connected and with higher correlation the higher network connectivity. Assessed at the Stroop task after MPH\Placebo according to the above time frames.

    Measured: 120 minutes

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Dec 2014 (estimated)
  2. Study startDec 2014
  3. Primary completionDec 2016 (estimated)
  4. Study completionDec 2017 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Allocation
Randomised
Intervention model
Crossover
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
75 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02318017
Sponsor's protocol ID
SHEBA-14-1351-IH-CTIL
Status last verified
Dec 2014
First submitted
18 Nov 2014
Last updated
17 Dec 2014
Results posted
No
Data monitoring committee
No

Publications

  • Rubinson M, Horowitz I, Naim-Feil J, Gothelf D, Moses E, Levit-Binnun N. Electroencephalography Functional Networks Reveal Global Effects of Methylphenidate in Youth with Attention Deficit/Hyperactivity Disorder. Brain Connect. 2019 Jun;9(5):437-450. doi: 10.1089/brain.2018.0630. Epub 2019 May 23.

    PubMed 30919658

Questions about this trial

What is this clinical trial studying?

A study testing Methylphenidate in people with Adhd, run by Sheba Medical Center at 1 site in Israel.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 17 Dec 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Itai Horowitz, MD (972503370579, itaizen@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Baseline Complex Network connectivity before treatment - using electrodes signal correlation (P-value) (time frame: 0 minutes). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02318017, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Dec 2014.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in